关节腔内曲安奈德与生理盐水对膝骨关节炎患者膝关节软骨体积和疼痛的影响:一项随机临床试验
这项为期2年的随机、安慰剂对照、双盲试验纳入140例有超声滑膜炎特征的症状性膝骨关节炎患者,比较每12周关节腔内注射曲安奈德40 mg与生理盐水对软骨体积丢失和疼痛的影响。结果显示曲安奈德组软骨体积丢失显著大于生理盐水组,而两组疼痛无显著差异。作者认为这些发现不支持对该患者群体使用此治疗。
要点
- 每3个月关节腔内注射曲安奈德40 mg持续2年,软骨体积丢失显著大于生理盐水。
- 两组间膝关节疼痛评分变化无显著差异。
- 作者认为这些发现不支持对症状性膝骨关节炎患者使用该治疗。
核心结论
- 在有症状的膝骨关节炎患者中,与关节腔内生理盐水相比,2年关节腔内曲安奈德治疗导致显著更大的软骨体积丢失,而膝关节疼痛无显著差异。
- 这些发现不支持对症状性膝骨关节炎患者使用该治疗。
研究设计与样本
- 为期2年的随机、安慰剂对照、双盲试验,比较关节腔内曲安奈德与生理盐水。
- 纳入140例符合美国风湿病学会症状性膝骨关节炎标准、Kellgren-Lawrence分级2或3级、且有超声滑膜炎特征的患者。
- 患者于2013年2月11日起在Tufts Medical Center入组,所有患者于2015年1月1日前完成研究。
- 干预为每12周关节腔内注射曲安奈德(n=70)或生理盐水(n=70),持续2年。
- 采用带随机截距的混合效应回归模型分析纵向重复结局指标。
主要发现
- 140例随机患者平均年龄58岁(SD,8),女性75例(54%),119例(85%)完成研究。
- 曲安奈德组导致显著大于生理盐水组的软骨体积丢失,指数间室软骨厚度平均变化为-0.21 mm vs -0.10 mm(组间差异,-0.11 mm;95% CI,-0.20至-0.03 mm)。
- 疼痛评分两组间无显著差异(-1.2 vs -1.9;组间差异,-0.6;95% CI,-1.6至0.3)。
- 生理盐水组有3例治疗相关不良事件,曲安奈德组有5例。
- 生理盐水组血红蛋白A1c水平有小幅升高(组间差异,-0.2%;95% CI,-0.5%至-0.007%)。
关键数值与推荐
- 疼痛采用西安大略和麦克马斯特大学骨关节炎指数(Likert疼痛亚量表范围0[无痛]至20[极度疼痛];最小临床重要改善为3.94)。
- 软骨体积通过每年膝关节磁共振成像定量评估(最小临床重要差异尚未定义)。
临床怎么用
- 原文结论指出这些发现不支持对症状性膝骨关节炎患者使用关节腔内曲安奈德治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Synovitis is common and is associated with progression of structural characteristics of knee osteoarthritis. Intra-articular corticosteroids could reduce cartilage damage associated with synovitis but might have adverse effects on cartilage and periarticular bone. OBJECTIVE: To determine the effects of intra-articular injection of 40 mg of triamcinolone acetonide every 3 months on progression of cartilage loss and knee pain. DESIGN, SETTING, AND PARTICIPANTS: Two-year, randomized, placebo-controlled, double-blind trial of intra-articular triamcinolone vs saline for symptomatic knee osteoarthritis with ultrasonic features of synovitis in 140 patients. Mixed-effects regression models with a random intercept were used to analyze the longitudinal repeated outcome measures. Patients fulfilling the American College of Rheumatology criteria for symptomatic knee osteoarthritis, Kellgren-Lawrence grades 2 or 3, were enrolled at Tufts Medical Center beginning February 11, 2013; all patients completed the study by January 1, 2015. INTERVENTIONS: Intra-articular triamcinolone (n = 70) or saline (n = 70) every 12 weeks for 2 years. MAIN OUTCOMES AND MEASURES: Annual knee magnetic resonance imaging for quantitative evaluation of cartilage volume (minimal clinically important difference not yet defined), and Western Ontario and McMaster Universities Osteoarthritis index collected every 3 months (Likert pain subscale range, 0 [no pain] to 20 [extreme pain]; minimal clinically important improvement, 3.94). RESULTS: Among 140 randomized patients (mean age, 58 [SD, 8] years, 75 women [54%]), 119 (85%) completed the study. Intra-articular triamcinolone resulted in significantly greater cartilage volume loss than did saline for a mean change in index compartment cartilage thickness of -0.21 mm vs -0.10 mm (between-group difference, -0.11 mm; 95% CI, -0.20 to -0.03 mm); and no significant difference in pain (-1.2 vs -1.9; between-group difference, -0.6; 95% CI, -1.6 to 0.3). The saline group had 3 treatment-related adverse events compared with 5 in the triamcinolone group and had a small increase in hemoglobin A1c levels (between-group difference, -0.2%; 95% CI, -0.5% to -0.007%). CONCLUSIONS AND RELEVANCE: Among patients with symptomatic knee osteoarthritis, 2 years of intra-articular triamcinolone, compared with intra-articular saline, resulted in significantly greater cartilage volume loss and no significant difference in knee pain. These findings do not support this treatment for patients with symptomatic knee osteoarthritis. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01230424.
引用
- McAlindon TE, LaValley MP, Harvey WF, et al. Effect of Intra-articular Triamcinolone vs Saline on Knee Cartilage Volume and Pain in Patients With Knee Osteoarthritis: A Randomized Clinical Trial. JAMA. 2017. PMID: 28510679. doi:10.1001/jama.2017.5283
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。